Oral PD-L1 Inhibitors Crowd into the Clinic.

Cancer discovery 2023 Jan 09

filter terms:

all
compound
gene and proteins
show more »
show less «

The first oral PD-L1 inhibitor to enter clinical testing has been discontinued for toxicity reasons, but several other small-molecule drugs targeted at the same checkpoint molecule appear to be safe with antitumor activity demonstrated in early trials. Compared with antibodies, these oral agents could offer advantages of convenience, safety, and increased tissue penetration. ©2022 American Association for Cancer Research.